Vaxart, Inc. News Releases https://investors.aviragentherapeutics.com/ Vaxart, Inc. News Releases en Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress https://investors.aviragentherapeutics.com/news-releases/news-release-details/vaxart-announces-oral-presentation-clinical-data-oral-influenza SOUTH SAN FRANCISCO, Calif., April 2, 2018 — Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1 Mon, 02 Apr 2018 16:10:00 -0400 Vaxart, Inc. News Releases 14381 Vaxart to Present at the 17th Annual Needham Healthcare Conference https://investors.aviragentherapeutics.com/news-releases/news-release-details/vaxart-present-17th-annual-needham-healthcare-conference SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive officer of Vaxart , will Wed, 21 Mar 2018 08:00:00 -0400 Vaxart, Inc. News Releases 14346 Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance https://investors.aviragentherapeutics.com/news-releases/news-release-details/vaxart-expands-intellectual-property-portfolio-us-patent Issued Claims Cover High Yield Production Process of Phase 2 Antiviral SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT) a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the Wed, 07 Mar 2018 08:00:00 -0500 Vaxart, Inc. News Releases 14341 Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases https://investors.aviragentherapeutics.com/news-releases/news-release-details/vaxart-present-clinical-data-oral-norovirus-vaccine-program SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will present clinical data from two Phase 1 studies of its Fri, 02 Mar 2018 08:00:00 -0500 Vaxart, Inc. News Releases 14336 Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc. https://investors.aviragentherapeutics.com/news-releases/news-release-details/vaxart-inc-closes-merger-aviragen-therapeutics-inc Vaxart, Inc. Closes Merger with Aviragen Therapeutics, Inc. Combined Company Renamed Vaxart, Inc. and Will Begin Trading Under New Symbol NASDAQ: VXRT SOUTH SAN FRANCISCO, CA and ATLANTA, Feb. 13, 2018 — Vaxart, Inc. (NASDAQ: VXRT) today announced the completion of its merger with Aviragen Wed, 14 Feb 2018 00:00:00 -0500 Vaxart, Inc. News Releases 14091 Vaxart Provides Merger Update https://investors.aviragentherapeutics.com/news-releases/news-release-details/vaxart-provides-merger-update Fri, 09 Feb 2018 00:00:00 -0500 Vaxart, Inc. News Releases 14106 Vaxart Issues Statement Regarding Proposed Merger With Aviragen https://investors.aviragentherapeutics.com/news-releases/news-release-details/vaxart-issues-statement-regarding-proposed-merger-aviragen Wed, 31 Jan 2018 00:00:00 -0500 Vaxart, Inc. News Releases 14111 Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study https://investors.aviragentherapeutics.com/news-releases/news-release-details/vaxart-announces-its-oral-flu-vaccine-significantly-reduced-rate Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study   Wed, 31 Jan 2018 00:00:00 -0500 Vaxart, Inc. News Releases 14101 Vaxart Announces Positive Results for its Oral Norovirus Vaccine in Phase 1b Clinical Study https://investors.aviragentherapeutics.com/news-releases/news-release-details/vaxart-announces-positive-results-its-oral-norovirus-vaccine Vaxart Announces Positive Results for its Oral Norovirus Vaccine in Phase 1b Clinical Study   Mon, 30 Oct 2017 00:00:00 -0400 Vaxart, Inc. News Releases 14096 Aviragen Therapeutics and Vaxart Enter into Merger Agreement https://investors.aviragentherapeutics.com/news-releases/news-release-details/aviragen-therapeutics-and-vaxart-enter-merger-agreement-0 Mon, 30 Oct 2017 00:00:00 -0400 Vaxart, Inc. News Releases 14116